Nat Med:新方法检测循环肿瘤DNA效果良好

2014-04-23 佚名 生物360

本周的《自然-医学》报道了一种可测量循环肿瘤 DNA(ctDNA)的超灵敏方法, ctDNA 是用来定量病人癌症患病程度的非侵入式生物标记。该方法比现有的手段更有效,成本更便宜,灵敏度更高,并可用在携带不同肿瘤基因型的病人身上并且其复发型变异数据已知。 Maximilian Diehn 等人利用从超过 400 名患者身上采集的数据研发出了一套测序手段,可覆盖肺癌复发性基因突变。有了这种方法,他们在

本周的《自然-医学》报道了一种可测量循环肿瘤 DNA(ctDNA)的超灵敏方法, ctDNA 是用来定量病人癌症患病程度的非侵入式生物标记。该方法比现有的手段更有效,成本更便宜,灵敏度更高,并可用在携带不同肿瘤基因型的病人身上并且其复发型变异数据已知。

Maximilian Diehn 等人利用从超过 400 名患者身上采集的数据研发出了一套测序手段,可覆盖肺癌复发性基因突变。有了这种方法,他们在从二期患者身上获得的所有样本和从一期患者身上获得的半数样本中检测了特异性高的 ctDNA 。在治疗过程中,检测到 ctDNA 的数量跟肿瘤容积有关联,而治疗后,确认的患者与残留病体相符合,并且相比放射治疗手段,该方法的检测反应更佳。

由于该方法或许还能用作局部晚期和转移肿瘤的癌症筛查和遗传鉴定而无需进行活体检测,所以该方法或能用于癌症的临床个性化治疗。

原始出处:

Aaron M Newman, Scott V Bratman, Jacqueline To, Jacob F Wynne, Neville C W Eclov, Leslie A Modlin, Chih Long Liu, Joel W Neal, Heather A Wakelee, Robert E Merritt, Joseph B Shrager, Billy W Loo, Ash A Alizadeh & Maximilian Diehn. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine,6 April 2014; doi:10.1038/nm.3519

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880026, encodeId=e311188002626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 07 04:35:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903059, encodeId=aede1903059e4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 06 19:35:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484845, encodeId=2a381484845f3, content=<a href='/topic/show?id=35a050454a5' target=_blank style='color:#2F92EE;'>#循环肿瘤DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50454, encryptionId=35a050454a5, topicName=循环肿瘤DNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac107986109, createdName=ms1948154235210413, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606167, encodeId=a3a5160616e2c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
    2014-08-07 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880026, encodeId=e311188002626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 07 04:35:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903059, encodeId=aede1903059e4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 06 19:35:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484845, encodeId=2a381484845f3, content=<a href='/topic/show?id=35a050454a5' target=_blank style='color:#2F92EE;'>#循环肿瘤DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50454, encryptionId=35a050454a5, topicName=循环肿瘤DNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac107986109, createdName=ms1948154235210413, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606167, encodeId=a3a5160616e2c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880026, encodeId=e311188002626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 07 04:35:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903059, encodeId=aede1903059e4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 06 19:35:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484845, encodeId=2a381484845f3, content=<a href='/topic/show?id=35a050454a5' target=_blank style='color:#2F92EE;'>#循环肿瘤DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50454, encryptionId=35a050454a5, topicName=循环肿瘤DNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac107986109, createdName=ms1948154235210413, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606167, encodeId=a3a5160616e2c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880026, encodeId=e311188002626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 07 04:35:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903059, encodeId=aede1903059e4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Wed Aug 06 19:35:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484845, encodeId=2a381484845f3, content=<a href='/topic/show?id=35a050454a5' target=_blank style='color:#2F92EE;'>#循环肿瘤DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50454, encryptionId=35a050454a5, topicName=循环肿瘤DNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac107986109, createdName=ms1948154235210413, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606167, encodeId=a3a5160616e2c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 25 05:35:00 CST 2014, time=2014-04-25, status=1, ipAttribution=)]

相关资讯

Sci Rep:肿瘤血管,你来自何方

背景:血管化是实体瘤中肿瘤细胞不断增殖的基本保障。但关于肿瘤细胞中血管的形成方式我们知道得实在太少。尽管这方面的研究持续了数十年,许多经典的血管形成方式和关键的分子机制已被描述或阐明;尽管以索拉非尼和贝伐单抗为代表的抗血管疗法在临床肿瘤治疗中取得了一定成绩,但在对肿瘤血管的更深层次认识及将其作为干预靶标在肿瘤治疗中的作用依然充满太多未知。近年来,抗血管疗法始终无法褪去“仅有短期局部的疗效,可能促进

PNAS:绘制癌转移的发展史

肿瘤能够通过转移扩散到机体的其他部分,但人们对这一过程并不十分了解。此前,研究者们一直难以确定转移发生在原发瘤发育的什么阶段,或者特定转移瘤是否直接来自于原发瘤。现在,科学家们开发了一个简单的新方法,能够快速分析患者体内多个肿瘤位点之间的进化关系,为制定合适的治疗方案提供宝贵信息。 “构建患者体内所有肿瘤的‘家谱’,不仅可以帮助我们确定肿瘤之间的差异,还有助于了解肿瘤的发展史,”文章的通讯作

Scientist:肿瘤异质性VS靶向性治疗

现在,许多人将对抗癌症的希望寄托在“靶向性治疗”上。与传统的化疗药物相比,靶向性药物被认为效力更其强副作用也更少。然而,研究者们逐渐意识到自己低估了癌症最古老也最广为人知的特性,肿瘤异质性。人们发现,肿瘤异质性可以决定靶向性药物的成败,The Scientist杂志近日刊登文章,探讨了这个令人头疼的问题。 癌症可能发生在任何器官,不过最常受其影响的是乳腺、肺部、结直肠和前列腺。肿

Nat Med:让我们用高大上的方法来检测ctDNA吧

著名的JohnsHopkins大学最近的一项研究揭示了ctDNA(循环肿瘤DNA/circulatingtumor DNA)的真面目,它其实是一种具备广泛应用前景、高敏感性、高特异性的肿瘤标志物,且适用于多种肿瘤(STM:ctDNA,恶性肿瘤检测筛查利器)。但ctDNA的研究还处在社会主义初级阶段,很多关键问题还没有解决,例如ctDNA怎么被释放入血(可能来自CTC,也可能不是),仍需要大家一

肿瘤免疫治疗 从探索到希望

免疫系统是对抗癌症的强大武器,但研究人员仍在努力寻找控制免疫系统的方式。律师Mark Gorman第一个被确认的肿瘤是脖子左侧的一个小型黑色素瘤。医生移除其肿瘤后向他保证,癌症被治愈了。然而8年后,医生在1998年例行体检时发现Gorman的腹部有肿块,黑色素瘤已扩散到肝脏,该肿瘤缠绕在下腔静脉上,不能动手术。晚期黑色素瘤患者在确诊后通常会活6到10个月。Gorman的妹妹告诉他,美国科罗拉多

全国肿瘤登记中心:2014年中国肿瘤流行病谱

2010年中国肿瘤流行病学重要数据及解读    2010年入选的登记处共覆盖人群1亿5840余万人,其中城市人口占58.35%,农村人口占41.45%。2010年,全国估计新发恶性肿瘤病例约309万,死亡病例196万。    全 国恶性肿瘤发病率为235.23/10万(男性268.65/10万,女性200.21/10万),中国人口标化率(中标率)1